Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Virology Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DDX6 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant DDX6 Protein (Full-Length / Helicase Domain) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for ATPase assays and binding screens. |
View DDX6 Products |
| Gene Delivery | DDX6 Promise-ORF / Lentivirus Full-length human DDX6 ORF for stable cell line generation and overexpression validation. |
View DDX6 Products |
| Benchmark Ab | Anti-DDX6 Recombinant Antibody High-affinity positive control for Western Blot, Immunofluorescence (P-body localization), and IP. |
View DDX6 Products |
| Validator | DDX6 siRNA Set Target-specific siRNA pool for target knockdown verification and functional rescue assays. |
View DDX6 Products |
| Related Target A | LSM14A Key P-body assembly partner that directly interacts with DDX6; critical for translation repression studies. |
View LSM14A Products |
| Related Target B | EIF4ENIF1 (4E-T) Nucleocytoplasmic shuttling protein that binds DDX6 to repress translation; crucial target for PPI disruption assays. |
View EIF4ENIF1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ATPase Activity Verification | Recombinant DDX6 proteins are sequence-verified and purified under native conditions to preserve enzymatic folding. |
| Protein-Protein Interaction (PPI) Screening | High-purity partner proteins (LSM14A, 4E-T) available for robust AlphaLISA or TR-FRET assay setup. |
| Specificity & Off-Target Screening | Broad panel of related DEAD-box helicases (DDX3X, DDX5) available to ensure small-molecule selectivity. |
| In Vivo / Cellular Validation | Endotoxin-controlled transfection-grade plasmids and high-titer lentiviral particles for stable cell line development. |
Live DDX6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of RNA-binding proteins and helicases has emerged as a frontier in oncology and infectious diseases. DDX6 (RCK/p54), a key DEAD-box RNA helicase, acts as a central hub in mRNA decay and translation repression within processing bodies (P-bodies). In cancer, DDX6 is frequently overexpressed, driving the translation of critical oncogenes such as c-Myc, VEGF, and cyclin D1. In virology, DDX6 serves as an essential host factor hijacked by positive-strand RNA viruses (including HCV, Zika, and Dengue) to facilitate viral replication.
The race for DDX6 therapeutics is intensifying, with major players shifting focus from traditional genetic knockdown to small-molecule inhibitors targeting the ATPase domain and PROTAC-mediated degradation. As first-generation chemical scaffolds enter preclinical optimization, the next wave of R&D is targeting the specific disruption of the DDX6-LSM14A or DDX6-4E-T protein-protein interactions to selectively derepress oncogenic mRNAs without global toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic Consortia, Biotech Startups | Solid Tumors (Colorectal, Breast), Viral Infections | High-throughput ATPase assays (Need high-purity, enzymatically active DDX6 recombinant protein) |
| PROTAC / Degrader | Targeted Protein Degradation (TPD) Firms | Refractory Cancers, Hematological Malignancies | Ternary complex formation assays (Need sequence-verified DDX6 and E3 ligase pathway proteins) |
| RNAi / Antisense | RNA Therapeutics Pioneers | Oncology, Chronic Viral Infections | Target knockdown validation (Need high-specificity DDX6 siRNA and qPCR/WB controls) |